Pfizer says its experimental drug for deadly condition that causes appetite and weight loss in cancer patients shows positive trial results
The results could pave the way for Pfizer's drug ponsegromab to become the first-ever approved treatment specifically for cancer cachexia.
Drug breakthrough provides new hope for cancer patients with cachexia
Researchers discovered a drug that safely and effectively helped cancer patients when they suffered from cachexia (ku-KEK-see-uh), a common condition related to cancer that involves weight loss and muscle wasting.
New cancer cachexia treatment boosts weight gain and patient activity
A nationwide clinical trial shows positive results for cancer patients with this common wasting syndrome. Researchers discovered a drug that safely and effectively helped cancer patients when they suffered from cachexia (ku-KEK-see-uh), a common condition related to cancer that involves weight loss and muscle wasting.
Pfizer drug shows promise in cancer-related condition that causes weight loss and weakness
Pfizer reported at #ESMO that an experimental antibody helped cancer patients with a condition known as cachexia.
Pfizer Drug Treating Fatal Weight Loss in Cancer Patients Found Effective
Pharma giant Pfizer said that a drug aimed at helping cancer patients losing appetite and muscle mass showed positive results in a Phase 2 trial.
ESMO: Pfizer sees weight gain in cancer patients, aims to enter phase 3 in 2025
Cancer patients with wasting syndrome have gained weight after taking Pfizer’s anti-GDF-15 antibody in a midphase study, emboldening the Big Pharma to target a 2025 start date for its pivotal trial program.
Pfizer therapy succeeds in mid-stage trial for cancer-related weight loss
Pfizer's (PFE) experimental therapy for cancer related weight loss, ponsegromab, meets the primary endpoint in Phase 2 trial. Read more here.
Pfizer drug helped cancer patients regain lost weight, study shows
Pfizer’s experimental cancer weight loss drug helped patients regain weight in a mid-stage study giving fresh promise for the dangerous muscle-wasting condition
KOIN Portland on MSN12h
New OHSU study shows promise in treating ‘urgent, unmet need’ in cancer patients
A new study from OHSU is claiming to show promise in the treatment of what they are calling an "urgent, unmet need" in cancer ...
Pfizer: Potential cachexia cancer drug shows life-saving promise
A drug that could reduce the risk of death in cancer patients is showing good promise during its second phase of clinical ...
Pfizer Advances On Its Cancer Journey
Pfizer Inc (NYSE: PFE) presented positive trial data for experimental drug designed for patients suffering from cancer ...
Optimistic Buy Rating for Artelo Biosciences Amidst Growing Focus on Cancer Cachexia Therapies
Maxim Group analyst Jason McCarthy maintained a Buy rating on Artelo Biosciences (ARTL – Research Report) yesterday and set a price ...
The Pharma Letter5d
ESMO 2024: Positive Phase II results for Pfizer’s ponsegromab in cancer cachexia
The Phase II study of ponsegromab, a monoclonal antibody directed against growth differentiation factor-15 (GDF-15), met its ...
Medpage Today on MSN3d
Novel Agent Effective for Cancer Wasting Disorder
Patients with cancer cachexia and an elevated level of growth differentiation factor 15 (GDF-15) achieved significant ...
Pfizer : Phase 2 Study Of Ponsegromab In Cancer Cachexia Meets Primary Endpoint
Pfizer Inc. (PFE) said Saturday that its Phase 2 study of ponsegromab, a monoclonal antibody directed against growth differentiation ...